Dr. Kahl on ADCT-402 for Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
Brad S. Kahl, MD, professor, Department of Medicine, Oncology Division, Washington University School of Medicine, discusses ADCT-402 for patients with relapsed/refractory B-cell lineage non-Hodgkin lymphoma.
Brad S. Kahl, MD, professor, Department of Medicine, Oncology Division, Washington University School of Medicine, discusses ADCT-402 for patients with relapsed/refractory B-cell lineage non-Hodgkin lymphoma.
ADCT-402 is a novel antibody-drug conjugate targeting CD19, explains Kahl. In the dose-escalation trial, there have been over 60 patients enrolled.
Overall response rates have been seen to be around 60% with complete response rates at approximately 40%. This is impressive looking at the patient population for this study, where there are currently no beneficial treatments existing, states Kahl.
